465 studies on Tirzepatide curated from PubMed, ClinicalTrials.gov, and EuropePMC. Updated daily.
This study provides compelling evidence that tirzepatide offers significant and broad cardiovascular protection beyond its established glycemic and weight-loss benefits, positioning it as a leading therapy for Type 2 …
This landmark study provides compelling evidence that Tirzepatide, a dual GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptor agonist, offers substantial cardiovascular prot…
These findings are profoundly significant, as they establish Tirzepatide as a potent agent for cardiovascular risk reduction in patients with Type 2 Diabetes and existing cardiovascular disease, moving beyond its know…
The findings from SURPASS-CVOT establish tirzepatide as a potent therapeutic agent for reducing cardiovascular risk in patients with type 2 diabetes, offering benefits beyond its metabolic effects. This is particularl…
GLP-1 RAs represent a highly promising pharmacological approach for managing prediabetes and actively preventing its progression to type 2 diabetes. Their dual action on glucose control and weight loss addresses key p…
This trial is crucial because it seeks to establish tirzepatide as a novel therapeutic option specifically for the reproductive and metabolic challenges faced by women with PCOS. If successful, the findings could sign…
The MAINTAIN study addresses a critical unmet need in obesity management, offering a potential solution to the widespread problem of weight regain after discontinuing GLP-1 RAs. GFMA could provide a durable, non-pharm…
Understanding tirzepatide's effects on skeletal muscle is critically important, as preserving muscle mass during weight loss is a key challenge, especially in obesity. If tirzepatide can mitigate muscle loss or even i…
This study is crucial for understanding Tirzepatide's long-term efficacy and safety outside of highly controlled clinical trial environments. If successful, the findings could significantly inform clinical guidelines …
This study provides compelling evidence that tirzepatide, when added to basal insulin, offers a highly effective strategy for achieving robust glycemic control and significant weight loss in Chinese patients with Type…
This novel evidence strongly suggests that tirzepatide could represent a groundbreaking therapeutic strategy for cocaine use disorder (CUD). Its dual action on GLP-1 and GIP receptors appears to modulate reward pathwa…
This first-of-its-kind case report strongly suggests that Tirzepatide, a dual GLP-1/GIP receptor agonist, may offer a novel and highly effective therapeutic avenue for Lichen Planus. The observed complete remission an…
This study underscores the increasing integration of GLP-1 RAs into the clinical management pathway for patients with severe obesity and related comorbidities who are considering sleep surgery. The observed significan…
Understanding GIP's long-term effects on bone is critically important given the widespread use of GIP receptor (GIPR) agonists like tirzepatide for obesity and type 2 diabetes, conditions often associated with comprom…
This study holds significant promise as it could identify a new, effective pharmacological treatment for severe forms of obesity like Prader-Willi Syndrome and hypothalamic obesity, which currently have limited therap…
This study is crucial as it addresses a significant unmet need for effective anti-obesity treatments in adult congenital heart disease (ACHD) patients, a population often excluded from major clinical trials. If succes…
The widespread adoption of GLP-1 receptor agonists means plastic surgeons are increasingly encountering patients with significant, rapid weight loss, necessitating a paradigm shift in surgical planning. This review pr…
This comprehensive meta-analysis provides strong evidence that Tirzepatide, a dual GIP/GLP-1 receptor agonist, offers superior glycemic control and weight loss benefits compared to Dulaglutide, a selective GLP-1 recep…
This study provides valuable real-world insights into the comparative safety profiles of tirzepatide, semaglutide, and liraglutide, which can complement findings from controlled clinical trials. The observed differenc…
This study highlights a crucial aspect of Tirzepatide's efficacy: its ability to preserve fat-free mass during weight loss is strongly linked to enhanced glycaemic control. This finding suggests that Tirzepatide offer…
The findings summarized in this review suggest that PentaPeptide-5 and similar multi-receptor agonists represent a significant advancement in the treatment of obesity and type 2 diabetes. By targeting multiple metabol…
This study holds significant promise for improving the health outcomes of people living with HIV who struggle with obesity and chronic inflammation. If successful, the findings could establish tirzepatide as a valuabl…
The discontinuation of GLP-1 agonists often leads to weight regain and a return of metabolic challenges, including elevated triglycerides, which are risk factors for cardiovascular disease. If RDX-002 proves effective…
This ongoing trial is crucial because it addresses a significant unmet medical need, potentially offering a new therapeutic option for adolescent obesity. If successful, the findings could establish tirzepatide as a s…
This study is crucial because it provides real-world evidence supporting Tirzepatide as a highly effective treatment intensification strategy for Type 2 Diabetes patients who are not adequately controlled on GLP-1 RAs…
The study, currently underway, aims to demonstrate the significant efficacy of Tirzepatide in reducing liver fat deposition in patients with Type 2 Diabetes and NAFLD with advanced fibrosis. Based on Tirzepatide's wel…
This research is critically important as it will provide evidence-based guidance for managing incretin-based therapies in patients undergoing upper endoscopy, potentially enhancing patient safety and procedural effici…
This case report highlights a rare but serious adverse event associated with tirzepatide use, particularly in individuals without pre-existing diabetes or obesity. Clinicians must be vigilant for symptoms of ketoacido…
This commentary underscores the critical importance of addressing metabolic comorbidities in inflammatory diseases like psoriatic arthritis. The hypothetical findings suggest that combining an IL-17A inhibitor with a …
This review highlights that obesity pharmacotherapy should be considered a disease-modifying component of Type 2 Diabetes (T2D) care, moving beyond mere weight reduction. The ability of these drugs to improve a broad …
This research provides compelling evidence that GLP-1 receptor agonists could represent a novel and effective strategy for smoking cessation. The observed reductions in nicotine seeking and withdrawal symptoms, couple…
This network meta-analysis provides crucial evidence that could significantly impact clinical guidelines for managing Type 2 Diabetes patients with high cardiovascular risk. The identification of specific GLP-1 recept…
This research provides robust real-world evidence confirming the effectiveness of GLP-1 therapies in a diverse Middle Eastern population, mirroring results from controlled clinical trials. The observed significant red…
This study provides critical safety reassurance regarding the use of these widely prescribed antidiabetic medications, particularly for hematologic malignancy risk. The agent-specific findings highlight the importance…
This case report is highly significant as it identifies a potential rare but serious adverse event associated with tirzepatide use in a patient population not traditionally considered at high risk for ketoacidosis. It…
This review provides strong evidence supporting Tirzepatide's potential as a highly effective therapeutic agent for Metabolically Dysfunctional-Associated Steatohepatitis (MASH), addressing a critical unmet medical ne…
The pervasive and devastating impact of addiction, affecting billions globally and incurring significant health, social, and economic costs, underscores the critical need for innovative treatment strategies. Incretin-…
A deeper understanding of the precise mechanisms underlying beta-cell stress and identity failure is absolutely crucial for the development of novel, disease-modifying therapeutic strategies for type 2 diabetes. This …
This research highlights the critical need for a more personalized approach to semaglutide therapy, moving beyond average treatment effects. Identifying predictors for suboptimal response could enable clinicians to ta…
This study powerfully underscores the chronic nature of obesity and the significant challenge of weight regain following tirzepatide discontinuation, emphasizing that sustained pharmacological intervention may be nece…
This pooled analysis strongly suggests that Tirzepatide is a highly effective add-on therapy for patients with Type 2 Diabetes who are not achieving optimal glycemic control with basal insulin alone. The dual action a…